Karyopharm Expects Preliminary Unaudited Full Year 2023 Total Revenue Of ~$146M vs $150.03M Est., Expects Prelim Q4 Revenue $33.6M vs $37.64M Est.
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics Inc. anticipates its preliminary unaudited full year 2023 total revenue to be around $146 million, which is below the estimated $150.03 million. The company also expects its preliminary Q4 revenue to be $33.6 million, falling short of the estimated $37.64 million.
January 08, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Karyopharm Therapeutics Inc. reported lower than expected preliminary revenues for both FY2023 and Q4, which may negatively impact investor sentiment and the stock price in the short term.
Revenue figures are a critical indicator of a company's financial performance. Karyopharm's announcement of revenues that are lower than analysts' estimates for both the full year and Q4 is likely to disappoint investors. This could lead to a negative short-term reaction in the stock market as investors adjust their expectations based on the new information.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100